[
  {
    "ts": null,
    "headline": "Janus Henderson Research Fund Q2 2025 Commentary",
    "summary": "Janus Henderson Research Fund returned 20.45% and the Russell 1000Â® Growth Index returned 17.84%. Read more here.",
    "url": "https://finnhub.io/api/news?id=8bdafe5707eab551d698d890a4af790f39ae0cab799ae275e30daf9ded83a902",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754523000,
      "headline": "Janus Henderson Research Fund Q2 2025 Commentary",
      "id": 136243862,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1954841243/image_1954841243.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Janus Henderson Research Fund returned 20.45% and the Russell 1000Â® Growth Index returned 17.84%. Read more here.",
      "url": "https://finnhub.io/api/news?id=8bdafe5707eab551d698d890a4af790f39ae0cab799ae275e30daf9ded83a902"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday",
    "summary": "When  Eli Lilly  reports its financial results early Thursday, investors will be looking for the company to press its advantage in the booming weight-loss drug market.  Competitor  Novo Nordisk  has fallen behind Lilly, as Lilly’s weight-loss shot Zepbound has seized a commanding majority of U.S. obesity prescriptions over Novo’s Wegovy.  On Wednesday, Novo Nordisk presented data showing that Zepbound now accounts for 59% of U.S.-branded weight-loss prescriptions, while Wegovy has just 40%.",
    "url": "https://finnhub.io/api/news?id=45221b3e09e5284f7727eea3d374b03be681c9a917f8b2520d67597b2d90dc9b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754512440,
      "headline": "Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday",
      "id": 136242440,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "When  Eli Lilly  reports its financial results early Thursday, investors will be looking for the company to press its advantage in the booming weight-loss drug market.  Competitor  Novo Nordisk  has fallen behind Lilly, as Lilly’s weight-loss shot Zepbound has seized a commanding majority of U.S. obesity prescriptions over Novo’s Wegovy.  On Wednesday, Novo Nordisk presented data showing that Zepbound now accounts for 59% of U.S.-branded weight-loss prescriptions, while Wegovy has just 40%.",
      "url": "https://finnhub.io/api/news?id=45221b3e09e5284f7727eea3d374b03be681c9a917f8b2520d67597b2d90dc9b"
    }
  },
  {
    "ts": null,
    "headline": "Is It Time to Buy Biotech Stocks?",
    "summary": "A surge in private market investment has investors wondering: Is it time to bet bigger on biotech?",
    "url": "https://finnhub.io/api/news?id=33eac44a9d3205dfed51048f5bc403ac1203a8d1653bbc084ed9691500e72e59",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754512080,
      "headline": "Is It Time to Buy Biotech Stocks?",
      "id": 136242442,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A surge in private market investment has investors wondering: Is it time to bet bigger on biotech?",
      "url": "https://finnhub.io/api/news?id=33eac44a9d3205dfed51048f5bc403ac1203a8d1653bbc084ed9691500e72e59"
    }
  },
  {
    "ts": null,
    "headline": "Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO",
    "summary": "Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better results.",
    "url": "https://finnhub.io/api/news?id=cdfcc86776946317aea69d5a789399027256f71c00b9f8470101c5a974830dfc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754503469,
      "headline": "Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO",
      "id": 136240000,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better results.",
      "url": "https://finnhub.io/api/news?id=cdfcc86776946317aea69d5a789399027256f71c00b9f8470101c5a974830dfc"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Q2 Preview: Can Mounjaro and Zepbound Keep Delivering?",
    "summary": "Street sees $5.60 EPS on $14.7B revenue as investors weigh drug demand strength.",
    "url": "https://finnhub.io/api/news?id=4d8bc5d675988a37470b0942f6644ef42ddaf2b09480480292a868a4e7ceae95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754502817,
      "headline": "Eli Lilly Q2 Preview: Can Mounjaro and Zepbound Keep Delivering?",
      "id": 136240856,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Street sees $5.60 EPS on $14.7B revenue as investors weigh drug demand strength.",
      "url": "https://finnhub.io/api/news?id=4d8bc5d675988a37470b0942f6644ef42ddaf2b09480480292a868a4e7ceae95"
    }
  },
  {
    "ts": null,
    "headline": "No Alzheimer’s Drug for Old Men?",
    "summary": "No Alzheimer’s Drug for Old Men?",
    "url": "https://finnhub.io/api/news?id=5d2c02c577c39b352c243070eebbe0df0df328fc2323e8a3e49ba04d721798e7",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754502060,
      "headline": "No Alzheimer’s Drug for Old Men?",
      "id": 136296146,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "No Alzheimer’s Drug for Old Men?",
      "url": "https://finnhub.io/api/news?id=5d2c02c577c39b352c243070eebbe0df0df328fc2323e8a3e49ba04d721798e7"
    }
  },
  {
    "ts": null,
    "headline": "LifeMD Stock Plummets 40%. Why Weight Loss Isn't Just A Gimme.",
    "summary": "LifeMD Stock Plummets 40%. Why Weight Loss Isn't Just A Gimme.",
    "url": "https://finnhub.io/api/news?id=e75e03548cb79ca74be6a34280c8f30858a2112ae5ac9ea98e6aee54ac15d09e",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754499076,
      "headline": "LifeMD Stock Plummets 40%. Why Weight Loss Isn't Just A Gimme.",
      "id": 136296147,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "LifeMD Stock Plummets 40%. Why Weight Loss Isn't Just A Gimme.",
      "url": "https://finnhub.io/api/news?id=e75e03548cb79ca74be6a34280c8f30858a2112ae5ac9ea98e6aee54ac15d09e"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Q2 Earnings Beat, Sales Miss, GLP-1 Drugs Face US Hurdles",
    "summary": "NVO's Q2 earnings beat but revenues miss estimates as Wegovy and Ozempic face U.S. setbacks and rising competition.",
    "url": "https://finnhub.io/api/news?id=f64f6dd994a9847d0ec5d78a531da6fa90c9756d5e7e53cd45eb15aa8f4bf4bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754496960,
      "headline": "Novo Nordisk Q2 Earnings Beat, Sales Miss, GLP-1 Drugs Face US Hurdles",
      "id": 136240002,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVO's Q2 earnings beat but revenues miss estimates as Wegovy and Ozempic face U.S. setbacks and rising competition.",
      "url": "https://finnhub.io/api/news?id=f64f6dd994a9847d0ec5d78a531da6fa90c9756d5e7e53cd45eb15aa8f4bf4bc"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Innovative Medicine’s Tremfya Gains Momentum in Crohn’s Disease, Outpacing Eli Lilly’s Omvoh and Challenging AbbVie’s Skyrizi",
    "summary": "Strong efficacy and safety perceptions, as well as favorable administration fuel utilization of the IL-23 class in Crohn’s disease, according to Spherix Global Insights.EXTON, PA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The Crohn’s disease (CD) treatment landscape is undergoing a radical transformation as newer mechanisms of action (MOAs), particularly IL-23 inhibitors and JAK inhibitors, continue displace long-standing therapies like TNF inhibitors. With the recent FDA approvals of Tremfya (guselkuma",
    "url": "https://finnhub.io/api/news?id=a9a707bf26bdf0acd2c2b56907ba2d4e4e4855af906cfc93b8196b3f35e10e4f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754494140,
      "headline": "Johnson & Johnson Innovative Medicine’s Tremfya Gains Momentum in Crohn’s Disease, Outpacing Eli Lilly’s Omvoh and Challenging AbbVie’s Skyrizi",
      "id": 136238959,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Strong efficacy and safety perceptions, as well as favorable administration fuel utilization of the IL-23 class in Crohn’s disease, according to Spherix Global Insights.EXTON, PA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The Crohn’s disease (CD) treatment landscape is undergoing a radical transformation as newer mechanisms of action (MOAs), particularly IL-23 inhibitors and JAK inhibitors, continue displace long-standing therapies like TNF inhibitors. With the recent FDA approvals of Tremfya (guselkuma",
      "url": "https://finnhub.io/api/news?id=a9a707bf26bdf0acd2c2b56907ba2d4e4e4855af906cfc93b8196b3f35e10e4f"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Is Dropping After Earnings. It Got Worse.",
    "summary": "The drugmaker released its second-quarter earnings report early Wednesday as it vowed to cut costs amid intensifying competition and a cratering stock price.",
    "url": "https://finnhub.io/api/news?id=8505dc34bc756ff90e2e6c1b1939543dc8aa9ba5262094ec51611737a76821b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754490600,
      "headline": "Novo Nordisk Stock Is Dropping After Earnings. It Got Worse.",
      "id": 136238304,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The drugmaker released its second-quarter earnings report early Wednesday as it vowed to cut costs amid intensifying competition and a cratering stock price.",
      "url": "https://finnhub.io/api/news?id=8505dc34bc756ff90e2e6c1b1939543dc8aa9ba5262094ec51611737a76821b2"
    }
  },
  {
    "ts": null,
    "headline": "Amgen's Q2 Earnings & Sales Beat Estimates, 2025 View Raised Slightly",
    "summary": "Amgen posts strong Q2 beats on earnings and sales, driven by double-digit drug volume gains.",
    "url": "https://finnhub.io/api/news?id=b46ba3b9300f7d308adca484ee62121596ed365da9fd22cf49eced07e30fed88",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754488260,
      "headline": "Amgen's Q2 Earnings & Sales Beat Estimates, 2025 View Raised Slightly",
      "id": 136238310,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Amgen posts strong Q2 beats on earnings and sales, driven by double-digit drug volume gains.",
      "url": "https://finnhub.io/api/news?id=b46ba3b9300f7d308adca484ee62121596ed365da9fd22cf49eced07e30fed88"
    }
  },
  {
    "ts": null,
    "headline": "GLP-1 \"Arms Race\" Broadens to Include Dozens of Companies",
    "summary": "Lexaria highlights DehydraTECH's adverse events improvement opportunity KELOWNA, BC / ACCESS Newswire / August 6, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the \"Company\" or \"Lexaria\"), a global innovator in drug delivery platforms, ...",
    "url": "https://finnhub.io/api/news?id=3e141e2c3c0cf518e1b0f0af56f6d2273f97e52b6d99b34e64122525c152d47e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754486400,
      "headline": "GLP-1 \"Arms Race\" Broadens to Include Dozens of Companies",
      "id": 136237164,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lexaria highlights DehydraTECH's adverse events improvement opportunity KELOWNA, BC / ACCESS Newswire / August 6, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the \"Company\" or \"Lexaria\"), a global innovator in drug delivery platforms, ...",
      "url": "https://finnhub.io/api/news?id=3e141e2c3c0cf518e1b0f0af56f6d2273f97e52b6d99b34e64122525c152d47e"
    }
  },
  {
    "ts": null,
    "headline": "Novo pushes back against obesity drug compounders as competition intensifies",
    "summary": "The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its slipping position in the lucrative market for weight loss drugs.",
    "url": "https://finnhub.io/api/news?id=571d95073e25707887d19e6f2b6e190fdb8d834242c3c4dc115904318bb46a41",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754482860,
      "headline": "Novo pushes back against obesity drug compounders as competition intensifies",
      "id": 136238962,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its slipping position in the lucrative market for weight loss drugs.",
      "url": "https://finnhub.io/api/news?id=571d95073e25707887d19e6f2b6e190fdb8d834242c3c4dc115904318bb46a41"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Drops After Earnings. It Got Worse.",
    "summary": "The drugmaker released its second-quarter earnings report early Wednesday as it vowed to cut costs amid intensifying competition and a cratering stock price.",
    "url": "https://finnhub.io/api/news?id=7ba409621e9e91f7df5813a643b262738aa53a43467023669ab0585b59a8480c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754482320,
      "headline": "Novo Nordisk Stock Drops After Earnings. It Got Worse.",
      "id": 136237165,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The drugmaker released its second-quarter earnings report early Wednesday as it vowed to cut costs amid intensifying competition and a cratering stock price.",
      "url": "https://finnhub.io/api/news?id=7ba409621e9e91f7df5813a643b262738aa53a43467023669ab0585b59a8480c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Co (LLY) Traded Lower in Q2 Despite Good Results",
    "summary": "Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” second quarter 2025 investor letter. A copy of the letter can be downloaded here. In 2025’s second quarter, tariffs triggered market declines and recession fears, but a pause in tariffs sparked a historic rally as earnings remained resilient. In the second […]",
    "url": "https://finnhub.io/api/news?id=d761ecfc7192b1c28a101a33d0551231d1d5146bd8a4d647b07a3267625a268e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754481279,
      "headline": "Eli Lilly and Co (LLY) Traded Lower in Q2 Despite Good Results",
      "id": 136237166,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” second quarter 2025 investor letter. A copy of the letter can be downloaded here. In 2025’s second quarter, tariffs triggered market declines and recession fears, but a pause in tariffs sparked a historic rally as earnings remained resilient. In the second […]",
      "url": "https://finnhub.io/api/news?id=d761ecfc7192b1c28a101a33d0551231d1d5146bd8a4d647b07a3267625a268e"
    }
  },
  {
    "ts": null,
    "headline": "Top 50 High-Quality Dividend Stocks For August 2025",
    "summary": "My investable universe of 50 high-quality dividend growth stocks aims to identify attractive opportunities based on valuation and future return potential.",
    "url": "https://finnhub.io/api/news?id=0f2b197bd42ff70f58a12c008358ad3352486b27942932257b51b6972fdbc4c0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754481040,
      "headline": "Top 50 High-Quality Dividend Stocks For August 2025",
      "id": 136238375,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2156211986/image_2156211986.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "My investable universe of 50 high-quality dividend growth stocks aims to identify attractive opportunities based on valuation and future return potential.",
      "url": "https://finnhub.io/api/news?id=0f2b197bd42ff70f58a12c008358ad3352486b27942932257b51b6972fdbc4c0"
    }
  },
  {
    "ts": null,
    "headline": "How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings",
    "summary": "Eli Lilly and Company (NYSE:LLY) will release earnings results for the second quarter before the opening bell on Thursday, Aug. 7. Analysts expect the health care company to report quarterly earnings at $5.59 per share, up from $3.92 per share in the year-ago period. Eli Lilly projects to report quarterly revenue of $14.67 billion, compared to $11.3 billion a year earlier, according to data from Benzinga Pro. With the recent buzz around Eli Lilly, some investors may be eyeing potential gains fro",
    "url": "https://finnhub.io/api/news?id=5125068695585372431917e08263550e33ac68ada198098e44b97f7d2449ee3d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754480504,
      "headline": "How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings",
      "id": 136232190,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) will release earnings results for the second quarter before the opening bell on Thursday, Aug. 7. Analysts expect the health care company to report quarterly earnings at $5.59 per share, up from $3.92 per share in the year-ago period. Eli Lilly projects to report quarterly revenue of $14.67 billion, compared to $11.3 billion a year earlier, according to data from Benzinga Pro. With the recent buzz around Eli Lilly, some investors may be eyeing potential gains fro",
      "url": "https://finnhub.io/api/news?id=5125068695585372431917e08263550e33ac68ada198098e44b97f7d2449ee3d"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk reports second quarter earnings missing Wall Street estimates on slower GLP-1 sales",
    "summary": "Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.",
    "url": "https://finnhub.io/api/news?id=9247d27f284d2c73bcdb0e2e0ee2f9166960832c77c738dffbe572d3f98f6699",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754477243,
      "headline": "Novo Nordisk reports second quarter earnings missing Wall Street estimates on slower GLP-1 sales",
      "id": 136232191,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.",
      "url": "https://finnhub.io/api/news?id=9247d27f284d2c73bcdb0e2e0ee2f9166960832c77c738dffbe572d3f98f6699"
    }
  },
  {
    "ts": null,
    "headline": "Wegovy maker Novo Nordisk to cut costs as competition grows",
    "summary": "STORY: Novo Nordisk said Wednesday it would cut costs as it takes on growing competition.The Danish firm faces a growing challenge from U.S. giant Eli Lilly, as well as copycat versions of its own Wegovy obesity drug.Now Novo expects lower growth for its treatments in the second half of the year.The firm became Europe's most valuable company last year, worth some $650 billion, due to the popularity of its blockbuster weight-loss drug.But shares have since tumbled, and it now faces a key moment as competition surges.Novo warned on profits last week and replaced its CEO - moves which wiped $95 billion off its market value.The company repeated its full-year guidance on Wednesday, a day before CEO Maziar Mike Doustdar was due to take charge.He faces tough questions about how Novo can stay competitive in the booming weight-loss drug market.The company confirmed a sales growth forecast for this year of between 8% and 14%.That was down from the previous forecast of up to 21%, and the second time this year the company has cut its outlook.Novo reported second-quarter sales of close to $12 billion - up 18% from last year, but below analyst expectations.",
    "url": "https://finnhub.io/api/news?id=47e544a7bed8ffdaef0119ba5ecce8231cc35eab6f8f0faecbed66b7e348be40",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754475043,
      "headline": "Wegovy maker Novo Nordisk to cut costs as competition grows",
      "id": 136232192,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "STORY: Novo Nordisk said Wednesday it would cut costs as it takes on growing competition.The Danish firm faces a growing challenge from U.S. giant Eli Lilly, as well as copycat versions of its own Wegovy obesity drug.Now Novo expects lower growth for its treatments in the second half of the year.The firm became Europe's most valuable company last year, worth some $650 billion, due to the popularity of its blockbuster weight-loss drug.But shares have since tumbled, and it now faces a key moment as competition surges.Novo warned on profits last week and replaced its CEO - moves which wiped $95 billion off its market value.The company repeated its full-year guidance on Wednesday, a day before CEO Maziar Mike Doustdar was due to take charge.He faces tough questions about how Novo can stay competitive in the booming weight-loss drug market.The company confirmed a sales growth forecast for this year of between 8% and 14%.That was down from the previous forecast of up to 21%, and the second time this year the company has cut its outlook.Novo reported second-quarter sales of close to $12 billion - up 18% from last year, but below analyst expectations.",
      "url": "https://finnhub.io/api/news?id=47e544a7bed8ffdaef0119ba5ecce8231cc35eab6f8f0faecbed66b7e348be40"
    }
  },
  {
    "ts": null,
    "headline": "Is Wall Street Bullish or Bearish on Eli Lilly Stock?",
    "summary": "Eli Lilly shares have underperformed the broader market over the past year, but Wall Street analysts remain firmly bullish in the company’s long-term growth prospects.",
    "url": "https://finnhub.io/api/news?id=afb4c0660855c5fb7ec9134a68cdcc3b5bbc1eba11ec8281139f136d562e8439",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754473717,
      "headline": "Is Wall Street Bullish or Bearish on Eli Lilly Stock?",
      "id": 136232193,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly shares have underperformed the broader market over the past year, but Wall Street analysts remain firmly bullish in the company’s long-term growth prospects.",
      "url": "https://finnhub.io/api/news?id=afb4c0660855c5fb7ec9134a68cdcc3b5bbc1eba11ec8281139f136d562e8439"
    }
  },
  {
    "ts": null,
    "headline": "Novo CFO: US Wegovy, Ozempic Prices to Keep Falling",
    "summary": "The maker of Ozempic and Wegovy obesity drugs said some of the prices could come down, as President Trump called for drugmakers to immediately lower their prices for Medicaid. This comes as Novo Nordisk's sales showed the weakest growth in four years as the Danish drugmaker loses ground to Eli Lilly in the crucial US market for obesity drugs. Karsten Munk Knudsen spoke with Bloomberg's Francine Lacqua from Copenhagen.",
    "url": "https://finnhub.io/api/news?id=b1cd836c7e2556cd71f936347465a99e6284ce7bf7d3449ddd24295db11f76c3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754471621,
      "headline": "Novo CFO: US Wegovy, Ozempic Prices to Keep Falling",
      "id": 136232194,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The maker of Ozempic and Wegovy obesity drugs said some of the prices could come down, as President Trump called for drugmakers to immediately lower their prices for Medicaid. This comes as Novo Nordisk's sales showed the weakest growth in four years as the Danish drugmaker loses ground to Eli Lilly in the crucial US market for obesity drugs. Karsten Munk Knudsen spoke with Bloomberg's Francine Lacqua from Copenhagen.",
      "url": "https://finnhub.io/api/news?id=b1cd836c7e2556cd71f936347465a99e6284ce7bf7d3449ddd24295db11f76c3"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress.",
    "summary": "The drugmaker released its second-quarter earnings report early Wednesday as it vowed to cut costs amid intensifying competition and a cratering stock price.",
    "url": "https://finnhub.io/api/news?id=a9ef3206020ecd54e818c4732d5204fff7f63ee96b45a162f1c54422139706e7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754469900,
      "headline": "Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress.",
      "id": 136232195,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The drugmaker released its second-quarter earnings report early Wednesday as it vowed to cut costs amid intensifying competition and a cratering stock price.",
      "url": "https://finnhub.io/api/news?id=a9ef3206020ecd54e818c4732d5204fff7f63ee96b45a162f1c54422139706e7"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Stocks Have Been Beaten Up. The Case for Buying Now.",
    "summary": "Healthcare stocks have been the sick man of the  this year.  The  exchange-traded fund has fallen 3.7% this year, far worse than the S&P 500’s 7.1% rise.  The ETF includes everything from insurers to pharma companies to medical-device makers, and that diversity usually helps the group weather the tough times.",
    "url": "https://finnhub.io/api/news?id=9a8e4064a99bde35e95e225106c6771e3156aa6b8dc50846fccc1e9bb0a4e06f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754469000,
      "headline": "Healthcare Stocks Have Been Beaten Up. The Case for Buying Now.",
      "id": 136232196,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Healthcare stocks have been the sick man of the  this year.  The  exchange-traded fund has fallen 3.7% this year, far worse than the S&P 500’s 7.1% rise.  The ETF includes everything from insurers to pharma companies to medical-device makers, and that diversity usually helps the group weather the tough times.",
      "url": "https://finnhub.io/api/news?id=9a8e4064a99bde35e95e225106c6771e3156aa6b8dc50846fccc1e9bb0a4e06f"
    }
  },
  {
    "ts": null,
    "headline": "Disney Earnings, New Tariff Deadline, Fed Speakers: Still to Come This Week",
    "summary": "Earnings season marches on, with results from Eli Lilly, Walt Disney and McDonald’s among this week's highlights, along with President Trump's new tariff-hike deadline for many countries. Trump also said he would name replacements this week for Federal Reserve governor Adriana Kugler and Bureau of Labor Statistics chief Erika McEntarfer.",
    "url": "https://finnhub.io/api/news?id=7b0c10040e5055f3d4dfe6b96871d21c303e1ec61647d31d1c01ecd69cfe0c64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754464983,
      "headline": "Disney Earnings, New Tariff Deadline, Fed Speakers: Still to Come This Week",
      "id": 136232197,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Earnings season marches on, with results from Eli Lilly, Walt Disney and McDonald’s among this week's highlights, along with President Trump's new tariff-hike deadline for many countries. Trump also said he would name replacements this week for Federal Reserve governor Adriana Kugler and Bureau of Labor Statistics chief Erika McEntarfer.",
      "url": "https://finnhub.io/api/news?id=7b0c10040e5055f3d4dfe6b96871d21c303e1ec61647d31d1c01ecd69cfe0c64"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Breakfast Podcast: Novo Nordisk Trims Outlook On Rising Rivalry",
    "summary": "Novo Nordisk plans cost cuts amid slower Wegovy growth outlook. Disneyâs ESPN to acquire NFL media assets. OpenAI reportedly exploring share sale at $500B valuation.",
    "url": "https://finnhub.io/api/news?id=38ffd0e369e528edc2c045926fb44d20d2311cac9e4b9c76cdae9adee63c1130",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754462873,
      "headline": "Wall Street Breakfast Podcast: Novo Nordisk Trims Outlook On Rising Rivalry",
      "id": 136231911,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158305433/image_2158305433.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk plans cost cuts amid slower Wegovy growth outlook. Disneyâs ESPN to acquire NFL media assets. OpenAI reportedly exploring share sale at $500B valuation.",
      "url": "https://finnhub.io/api/news?id=38ffd0e369e528edc2c045926fb44d20d2311cac9e4b9c76cdae9adee63c1130"
    }
  },
  {
    "ts": null,
    "headline": "Baron Opportunity Fund Q2 2025 Shareholder Letter",
    "summary": "Baron Opportunity Fund posted solid gains for the quarter, outperforming its benchmark, the Russell 3000 Growth Index. Read more here.",
    "url": "https://finnhub.io/api/news?id=17fe6f507daece5e7d64361b6b20f81ddf6d6c8e4c0dc77e5f0fa0c37da50991",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754462760,
      "headline": "Baron Opportunity Fund Q2 2025 Shareholder Letter",
      "id": 136231878,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1158571591/image_1158571591.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Baron Opportunity Fund posted solid gains for the quarter, outperforming its benchmark, the Russell 3000 Growth Index. Read more here.",
      "url": "https://finnhub.io/api/news?id=17fe6f507daece5e7d64361b6b20f81ddf6d6c8e4c0dc77e5f0fa0c37da50991"
    }
  },
  {
    "ts": null,
    "headline": "Wegovy maker Novo Nordisk warns on continued copycat-drug challenge as new CEO readied",
    "summary": "COPENHAGEN (Reuters) -Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy obesity drug, as it battled pressure from compounding pharmacies in the United States and rival Eli Lilly.  The Danish drugmaker, which became Europe's most valuable company worth $650 billion last year on sales of its blockbuster weight-loss drug, is facing a pivotal moment as Wegovy loses market share, especially in the U.S.  Last week, competition from compounders - who make copycat medicines based on the same ingredients as Wegovy - prompted the company to cut its full-year sales and profit outlook.",
    "url": "https://finnhub.io/api/news?id=9c136519f42e93466e3dde84179bd873e215d5290afc4a3ab71b6766ebc46000",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754458572,
      "headline": "Wegovy maker Novo Nordisk warns on continued copycat-drug challenge as new CEO readied",
      "id": 136232198,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "COPENHAGEN (Reuters) -Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy obesity drug, as it battled pressure from compounding pharmacies in the United States and rival Eli Lilly.  The Danish drugmaker, which became Europe's most valuable company worth $650 billion last year on sales of its blockbuster weight-loss drug, is facing a pivotal moment as Wegovy loses market share, especially in the U.S.  Last week, competition from compounders - who make copycat medicines based on the same ingredients as Wegovy - prompted the company to cut its full-year sales and profit outlook.",
      "url": "https://finnhub.io/api/news?id=9c136519f42e93466e3dde84179bd873e215d5290afc4a3ab71b6766ebc46000"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk's weight loss challenge in five charts",
    "summary": "Danish drugmaker Novo Nordisk is facing a major challenge to its blockbuster weight-loss drug Wegovy. Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market capitalization since mid last year as competition from U.S. rival Eli Lilly and Co and copycat rivals has hardened. The firm, which reports second-quarter results on Wednesday, has appointed a new CEO, veteran insider Maziar Mike Doustdar, who will take the reins on Thursday, and now needs to win over investors skeptical he can turn the firm's fortunes around.",
    "url": "https://finnhub.io/api/news?id=5b202263afb24b08b36b872545f576a0e7459eb6e79d6d16c8d9959a187dd6a3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754456639,
      "headline": "Novo Nordisk's weight loss challenge in five charts",
      "id": 136232199,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Danish drugmaker Novo Nordisk is facing a major challenge to its blockbuster weight-loss drug Wegovy. Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market capitalization since mid last year as competition from U.S. rival Eli Lilly and Co and copycat rivals has hardened. The firm, which reports second-quarter results on Wednesday, has appointed a new CEO, veteran insider Maziar Mike Doustdar, who will take the reins on Thursday, and now needs to win over investors skeptical he can turn the firm's fortunes around.",
      "url": "https://finnhub.io/api/news?id=5b202263afb24b08b36b872545f576a0e7459eb6e79d6d16c8d9959a187dd6a3"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Earnings: What To Look For From LLY",
    "summary": "Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting earnings this Thursday before the bell. Here’s what investors should know.",
    "url": "https://finnhub.io/api/news?id=9fcf50429442e6073940779db3ecdd7c7db049a917a291450985abdf7af82623",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754450361,
      "headline": "Eli Lilly Earnings: What To Look For From LLY",
      "id": 136232200,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting earnings this Thursday before the bell. Here’s what investors should know.",
      "url": "https://finnhub.io/api/news?id=9fcf50429442e6073940779db3ecdd7c7db049a917a291450985abdf7af82623"
    }
  }
]